Patronus Biotech secures approval for Phase I malaria vaccine trials in Australia

Patronus Biotech has been granted ethical approval by Bellberry Limited to initiate its first-in-human clinical trials in Australia. The study will evaluate three multi-stage vaccine candidates designed to target Plasmodium falciparum and Plasmodium vivax, the parasites responsible for the majority of malaria cases globally.

The trial focuses on assessing the safety and tolerability of these VLP-based candidates in human subjects. By utilizing virus-like particles, the company aims to simulate a viral infection to trigger a robust immune response without the risk of actual infection, a methodology that is currently under intense scrutiny in vaccine development.

This Phase I trial represents a significant progression for Patronus Biotech. The data generated from this study will provide the necessary evidence to determine whether these candidates warrant advancement into larger, efficacy-focused trials.